NeueHealth Inc is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare... Show more
The 50-day moving average for NEUE moved above the 200-day moving average on November 21, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (4.128). P/E Ratio (1.189) is within average values for comparable stocks, (34.771). NEUE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.225). NEUE's Dividend Yield (0.000) is considerably lower than the industry average of (0.023). P/S Ratio (0.065) is also within normal values, averaging (0.664).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NEUE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Industry ManagedHealthCare
A.I.dvisor tells us that NEUE and PGNY have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NEUE and PGNY's prices will move in lockstep.
| Ticker / NAME | Correlation To NEUE | 1D Price Change % | ||
|---|---|---|---|---|
| NEUE | 100% | N/A | ||
| PGNY - NEUE | 24% Poorly correlated | -0.23% | ||
| CLOV - NEUE | 24% Poorly correlated | +0.40% | ||
| CVS - NEUE | 21% Poorly correlated | +1.38% | ||
| UNH - NEUE | 21% Poorly correlated | +0.86% | ||
| CI - NEUE | 21% Poorly correlated | +0.41% | ||
More | ||||
| Ticker / NAME | Correlation To NEUE | 1D Price Change % |
|---|---|---|
| NEUE | 100% | N/A |
| Publishing: Books/Magazines industry (28 stocks) | 5% Poorly correlated | -0.00% |
| Consumer Services industry (452 stocks) | 3% Poorly correlated | -0.00% |